Evidence map›Paper›PMID 22110720›Full record

ArticlePloS one2011

Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer.

ShanShan He, Feng Wang, LiJuan Yang, ChuanYong Guo, Rong Wan, AiWu Ke, Ling Xu, GuoYong Hu, XuanFu Xu, Jie Shen and 1 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Life science alliance · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. GermlineHaematologica · 2022
    Article
  9. Review
  10. Review
  11. Article
  12. The Relevance ofDiagnostics (Basel, Switzerland) · 2021
    Article
  13. Article
  14. Article
  15. Frontiers in oncology · 2021
    Review
  16. Review
  17. Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2019
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

ShanShan HeDepartment of Gastroenterology, Shanghai 10th People's Hospital, Tongji University, Shanghai, People's Republic of China.
Feng Wang
LiJuan Yang
ChuanYong Guo
Rong Wan
AiWu Ke
Ling Xu
GuoYong Hu
XuanFu Xu
Jie Shen
XingPeng Wang
Tongji University · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsGLI1, as an indispensable transcriptional factor of Hedgehog signaling pathway, plays an important role in the development of pancreatic cancer (PC). DNA methyltransferases (DNMTs) mediate the methylation of quantity of tumor-related genes. Our study aimed to explore the relationship between GLI1 and DNMTs.

methodsExpressions of GLI1 and DNMTs were detected in tumor and adjacent normal tissues of PC patients by immunohistochemistry (IHC). PANC-1 cells were treated by cyclopamine and GLI1-siRNA, while BxPC-3 cells were transfected with overexpression-GLI1 lentiviral vector. Then GLI1 and DNMTs expression were analyzed by qRT-PCR and western blot (WB). Then we took chromatin immunoprecipitation (ChIP) to demonstrate GLI1 bind to DNMT1. Finally, nested MSP was taken to valuate the methylation levels of APC and hMLH1, when GLI1 expression altered.

resultsIHC result suggested the expressions of GLI1, DNMT1 and DNMT3a in PC tissues were all higher than those in adjacent normal tissues (p<0.05). After GLI1 expression repressed by cyclopamine in mRNA and protein level (down-regulation 88.1±2.2%, 86.4±2.2%, respectively), DNMT1 and DNMT3a mRNA and protein level decreased by 91.6%±2.2% and 83.8±4.8%, 87.4±2.7% and 84.4±1.3%, respectively. When further knocked down the expression of GLI1 by siRNA (mRNA decreased by 88.6±2.1%, protein decreased by 63.5±4.5%), DNMT1 and DNMT3a mRNA decreased by 80.9±2.3% and 78.6±3.8% and protein decreased by 64.8±2.8% and 67.5±5.6%, respectively. Over-expression of GLI1 by GLI1 gene transfection (mRNA increased by 655.5±85.9%, and protein increased by 272.3±14.4%.), DNMT1 and DNMT3a mRNA and protein increased by 293.0±14.8% and 578.3±58.5%, 143.5±17.4% and 214.0±18.9%, respectively. ChIP assays showed GLI1 protein bound to DNMT1 but not to DNMT3a. Results of nested MSP demonstrated GLI1 expression affected the DNA methylation level of APC but not hMLH1 in PC.

conclusionDNMT1 and DNMT3a are regulated by GLI1 in PC, and DNMT1 is its direct target gene.

Indexed as

Gene Expression Regulation, NeoplasticAdenomatous Polyposis ColiCell Line, TumorDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3AHumansOncogene ProteinsPancreatic NeoplasmsPromoter Regions, GeneticRNA, Small InterferingTrans-ActivatorsUp-RegulationVeratrum AlkaloidsZinc Finger Protein GLI1cyclopamineDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT1 protein, humanDNMT3A protein, humanOncogene ProteinsRNA, Small InterferingTrans-ActivatorsVeratrum AlkaloidsZinc Finger Protein GLI1

Identifiers

PMID22110720
PMCPMC3215738
OpenAlexW2063619264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.